A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease that involves providing an individual with an effective amount of a composition of bacteria modified using a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system so that the bacteria is able to produce a therapeutically effective amount of anti-bodies to oxidized low density lipoprotein, with the modified bacteria preferably being from the Lactobacillus, Bifidobacterium, and Streptococcus species; and most preferably including L. reuteri bacteria modified using CRISPR-Cas and/or Cpf1 systems so that it is able to survive the conditions in the duodenum and jejunum of the small intestine of a human.

A gastric constriction device comprises a sheet extending over part of the wall of the stomach. Five bands extend around the stomach to fix the sheet in position relative to the stomach. The lower two bands extend from the first side of the sheet around the stomach only partially towards the second side. These lower two bands are not fixed to the second side. This arrangement results in an unconstricted portion of the stomach. In this manner, the device restricts expansion of the majority of the stomach wall while facilitating expansion of this unconstricted portion. The unconstricted portion is therefore free to expand or bulge outwardly upon ingestion. This expansion may trigger the feeling of satiation due to the presence of the vagal nerves in this portion of the stomach.

An apparatus for the treatment of acid reflux disease comprising two or more movement restriction device segments adapted to be movement restriction device of a controlled size. The movement restriction device can at least partly be invaginated by a patient's stomach fundus wall. A substantial part of the outer surface of the movement restriction device is adapted to rest against the stomach wall without injuring the latter in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen.

An apparatus for treating obesity comprises a volume filling device formed by at least two segments and is provided and following implantation, the device is placed resting against the stomach wall of the patient to reduce the inner volume of the stomach, thereby affecting the patients appetite.

A wearable apparatus for the treatment or prevention of osteopenia or osteoporosis, stimulating bone growth, preserving or improving bone mineral density, and inhibiting adipogenesis is disclosed where the apparatus may generally comprise one or more vibrating elements configured for imparting repeated mechanical loads to the hip, femur, and/or spine of an individual at a frequency and acceleration sufficient for therapeutic effect. These vibrating elements may be secured to the upper body of an individual via one or more respective securing mechanisms, where the securing mechanisms are configured to position the one or more vibrating elements in a direction lateral to the individual, and the position, tension, and efficacy of these vibrating elements may be monitored and/or regulated by one or more accelerometers.

An apparatus for applying a portion of a plant product to the epidermis of a human, the apparatus adapted to be removably fastened with a belt or strap to a human body, comprising: the belt or strap; at least one pocket or container adapted to removably receive the portion of the plant product, the at least one pocket or container comprising: a contact portion that contacts the human body, when the apparatus is removably fastened to the human body, an opposing portion, opposing the contact portion, the opposing portion adapted to allow the portion of the plant product to be removably inserted into the at least one pocket or container, the contact portion having a plurality of holes, the plurality of holes allowing the portion of the plant product to contact the epidermis, when the plant product is removably inserted into the at least one pocket or container.

An intraluminar method of treating obesity of a patient, having a stomach with a food cavity, is disclosed. The method comprises the steps of creating a pouch made of a stomach wall portion of the patient, closing the pouch by sutures, staples or a fixation device, and placing a volume filling device in the pouch before or after closing the pouch, and thus investigating the volume filling device in the pouch such that an outer surface of the volume filling device rests against an outer surface of the stomach wall.

A method for preventing obesity related to infection by an adipogenic adenovirus includes obtaining a sample from a person, assaying the sample to determine whether the person has been previously infected with an adipogenic adenovirus, and if the person has not been previously infected, providing the person with at least one sensor positioned to detect when a person's hand approaches a predetermined distance from the person's face. By warning the person of undesired hand-to-face contacts, the person is able to reduce the incidence of obesity related infections. Other embodiments are directed to a kit for preventing obesity caused by infection with an adipogenic adenovirus, such kit including a container for assaying an agent indicating the presence of antibodies to Ad-36, and a sensor positioned on an item selected from the group consisting of one of a hat, a writing instrument, eye glasses, a belt, sunglasses, a bra, a shirt, and a tie.

A gastrointestinal device for implanting within a patient's gastrointestinal tract, the device having a central axis and a first expandable portion comprising a hollow tubular braided structure of wire and having a first cylinder extending parallel to the central axis, the first cylinder having a length and a first face; a neck portion extending from the first face of the first expandable portion parallel to the central axis, the neck portion having a first end, a second end, a wall extending between the first end and second end, and a diameter sized to fit within a pylorus; and a second expandable portion comprising a hollow tubular braided structure of wire and having a second cylinder extending parallel to the central axis, the second cylinder having a second face located at the proximal end of the second cylinder and oriented transverse to the central axis.

An apparatus for treating reflux disease of a human patient. The apparatus comprising an implantable movement restriction device, having an outer surface that includes a biocompatible material. The movement restriction device is adapted to rest against and to be kept in place contacting the stomach fundus wall, without restricting food passage in the food passageway when implanted and in function, and without injuring the stomach fundus wall in a position between the patient's diaphragm and the cardia sphincter. The movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is thereby restricted, when the movement restriction device is implanted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax. The movement restriction device is adapted to contact directly or indirectly the diaphragm muscle to prevent such sliding of the cardia through the patient's diaphragm, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen. The movement restriction device having a size, when implanted and in function such that the functional movement restriction device can be completely invaginated by the stomach fundus of the human patient, and of at least 125 mm.sup.3, and a circumference of at least 15 mm.